X
XtalPi
Artificial intelligence (AI) pharmaceutical firm
At a glance
- Status
- Listed
- Listing
- IPO 2024
Open roles
XtalPi in the Shenzhen ecosystem
The XtalPi office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later13 investors entered at this stage
- MPMorningside Venture Partners
SoftBank- CIChina Life Insurance
- PCPICC Capital
5Y Capital- SBSino Biopharmaceutical
- RCRRJ Capital
- MTMassachusetts Institute of Technology
- SCSIG China
Sequoia
SoftBank Vision Fund
Alphabet | Google
OrbiMed
Source: Dealroom Talent Intelligence.
Patents
341 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where XtalPi was the backer or acquirer, 2020–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
19 deals across XtalPi's capital deployment.
Where the deals concentrate by sector, stage, and decade.
XtalPi's portfolio, mapped.
See XtalPi on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
XtalPi and Pierre Fabre join forces on AI-powered drug discovery
China's INFevo raises $15M early round for virtual cell AI
XtalPi launches Kodexia, an AI-driven platform for siRNA medicines, with six programmes advancing




